RxDoctor Payments Data

James Jackson, MD

Pulmonary Disease · Frankfort, KYNPI 1376542951

Payments from drug & device makers

$1,313in general payments, 2019–2025

Across 84 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$455
  • Boehringer Ingelheim$251
  • GSK$85
  • Novo Nordisk$68
  • AstraZeneca$62
  • Regeneron Healthcare Solutions, Inc.$50
  • plus $341 from 15 others

What the payments were for

  • Food & beverage$1,29999%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,313 in reported general payments places this provider in the 25th percentile of 226 pulmonary disease providers in Kentucky.

See all pulmonary disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$4,532
Medicare patients
29
Services billed
111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$64,033
XolairOmalizumab15$42,662
Spiriva RespimatTiotropium Bromide49$41,362
Spiriva HandihalerTiotropium Bromide54$35,689
Advair HfaFluticasone Propion/Salmeterol34$14,150
Breo ElliptaFluticasone/Vilanterol20$7,911
SymbicortBudesonide/Formoterol Fumarate23$7,639
Fluticasone-SalmeterolFluticasone Propion/Salmeterol51$7,178
Incruse ElliptaUmeclidinium Bromide18$5,411
Albuterol Sulfate HfaAlbuterol Sulfate84$3,256
Wixela InhubFluticasone Propion/Salmeterol23$3,076
Azithromycin218$1,788
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$1,184
Omeprazole71$366
Montelukast Sodium40$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$85$77,355104 claims
Boehringer IngelheimSpiriva Respimat$251$41,36249 claims
AstraZenecaSymbicort$62$7,63923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 226 pulmonary disease providers in Kentucky.

Other pulmonary disease in Frankfort

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →